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Estradiol, the most important hormone in females, was complexed
with hydroxypropyl-β-cyclodextrin (HP-β-CD) and randomly
methylated β-cyclodextrin (RM-β-CD). After obtaining the
inclusion complexes, they were characterized by DSC, 1H-NMR
and solubility studies. The enhancing effect of CDs on estradiol
skin permeation/retention was investigated in vitro using Franz
diffusion cells. Both CDs increased estradiol aqueous solubility,
but in different proportions. DSC and NMR-H1 analyses showed
that estradiol was complexed with both CDs and RM-β-CD has
stronger interactions with the hormone than HP-β-CD. Moreover,
complexes formation increased estradiol flux through the skin
(P<0.01), but the hormone retention in the stratum corneum (SC)
only increased after complexation with HP-β-CD. On the other
hand, only RM-β-CD was able to modify estradiol retention in the
SC after skin pretreatment with CDs. The results suggest that the
enhancing effect of CDs on estradiol flux through the skin may be
mainly described as an increase in drug availability on the skin
surface due to inclusion complexation. Furthermore, the formation
of a significant reservoir of estradiol in the SC due to HP-β-CD
complexation makes it an interesting approach for estradiol
transdermal delivery.
INTRODUCTION
Estrogen replacement therapy has been used for
postmenopausal symptoms prevention. Estradiol, the most
important estrogen in females, is responsible for
maintaining important physiological functions, such as bone
mineral density, thyroid function, cardiovascular system
health, mood, sexual function, skin elasticity and fertility
(Miller, Franklin, 1999; Kenemans et al., 2001). Although
the transdermal delivery of estradiol has shown more
advantages over oral administration, such as sustained drug
delivery, patient compliance improvement, side-effect
reduction and elimination of first-pass effect (Essa, Bonner,
Barry, 2004; Prausnitz, Mitragotri, Langer, 2004; Warming,
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Ravn Christiansen, 2005), the low aqueous solubility of
estradiol makes the development of new transdermal
delivery systems difficult.
In the pharmaceutical industry, cyclodextrins (CDs)
have mainly been used as complexing agents to increase the
aqueous solubility, availability, and stability of poorly water-
soluble drugs. CDs are cyclic (α-1,4)-linked oligosaccharides
of α-D-glucopyranose containing a relatively hydrophobic
central cavity and a hydrophilic external surface. The most
common CDs are α, β and γ-CD, which consist of six, seven
and eight glucopyranose units, respectively. In aqueous
environment, CDs are capable of forming inclusion complexes
with many drugs by incorporating a whole drug molecule or
at least some lipophilic moiety of a molecule into the cavity.
The complexes are readily dissociated and free drug
molecules are in relative equilibrium with drug molecules
bound within the CD cavity (Stella et al., 1999; Del Valle,
2004; Loftsson, Hreinsdóttir, Másson, 2005).
The rate-limiting barrier to transdermal drug delivery
is the outermost layer of skin, the stratum corneum (SC)
(Hadgraft, 2004). Conventional absorption enhancers,
such as alcohols and fatty acids, disrupt the lipid layers of
biological barriers, generally inducing skin irritation
(Williams, Barry, 2004). It has been demonstrated that
some modified β-CDs such as methylated α-CDs and
hydroxypropyl-β-CD (HP-β-CD) are able to interact with
lipophilic components of SC (Bentley et al., 1997;
Loftsson, Másson, 2001) and improve drug absorption
(Másson et al., 1999; Lopez, Collet, Bentley, 2000).
Moreover, methylated β-CDs are known to extract several
classes of lipids and therefore reduce the skin barrier,
acting as true absorption enhancers (Vollmer et al., 1994;
Matsuda, Arima, 1999; Babu, Pandit, 2004).
Thus, the present study reports the characterization
of estradiol inclusion complexes formed with two modified
CDs, HP-β-CD and randomly methylated-β-CD (RM-β-
CD), in solution and in solid state. Furthermore, the
influence of these CDs on the in vitro permeation/retention
of estradiol through hairless mouse skin was investigated.
MATERIAL AND METHODS
Material
HP-β-CD was obtained from TRAPPSOL (Gainesville,
Fl, USA). RM-β-CD and 17-β-estradiol (estra-1,3,5(10)-triene-
3,17β-diol) were obtained from SIGMA (St. Louis, MO, USA).
The degrees of substitution (number of substituted groups per
β-CD unit) were 4.4 and 1.7 for HP-β-CD and RM-β-CD,
respectively. All other reagents and salts were of analytical or
HPLC grade and were used as received.
Phase solubility studies
According to Higuchi and Connors (1965), excess
amounts of estradiol were added to aqueous solutions
containing various concentrations of HP-β-CD or RM-β-CD
(0 to 50.0 mM). Samples were maintained at 25 ºC and
stirred (300 rpm) for 24 h. Afterwards, samples were
filtered (0.45 μm), appropriately diluted in methanol and
analyzed at 280 nm using a HITACHI U-3501
spectrophotometer. The estradiol calibration curve was also
done in methanol. Apparent 1:1 stability constants (Kc) were
determined from the initial straight-line portion of the phase
solubility diagrams:
Kc =
Slope
So x (1 – Slope)
where (So) is the free estradiol aqueous solubility.
Solid complexes were obtained by lyophilization in
order to carry out physical characterization. The complexes
molar ratios were determined by UV measurements at
280 nm. Each experiment was conducted in triplicate
(coefficient of variation, CV<3%).
Differential scanning calorimetry measurements (DSC)
DSC measurements were conducted on NETZSCH
DSC 200 equipment. Each sample (solid inclusion
complexes, physical mixtures in a same equimolar ratio and
pure components) was weighed in open aluminum pans and
scanned at a heating rate of 5 ºC/min in the temperature
range between 25 and 250 ºC. Hydrogen was used as
purging gas. Indium (99.9%) was used as a standard for
calibration of the DSC equipment.
Nuclear magnetic resonance measurements (
1
H-NMR)
1H-NMR was carried out using a BRUKER DPX
spectrometer operating at 300 MHz. Samples (free estradiol
and solid complexes) were dissolved in D20:Deuterated
methanol (1:1). Tetramethylsilane was used as internal
reference with an accuracy of  ± 0.001 ppm. The conditions
for Fourier transform measurements were: acquisition time,
3.5 s; pulse angle, 30º; delay time, 2 s; number of spectra, 16.
Skin permeation studies
The permeation studies were performed in modified
Franz diffusion cells (Hanson Research) at 37 ºC during 24 h.
Full-thickness skin of male hairless mice HRS/J strain (4-6
weeks old), supplied by Jackson Laboratories (Bar Harbor,
ME, USA), was clamped between the donor and the recep-
tor phases with a diffusion area of 1.77 cm2. The receptor
compartment was filled with 7.0 mL of phosphate buffer
(0.1 M, pH 7.2) containing 10% (v/v) of ethanol in order to
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maintain sink conditions. PG:water (1:1) was used as vehicle
in the donor phase. Saturated solution of free estradiol (0.05%,
w/v) was used as a control group. Donor phases containing
estradiol/CDs complexes were used in an equivalent
concentration of 3.0% (w/v) of CDs, corresponding to 0.18%
(w/v) and 0.2% (w/v) of estradiol for HPCD and RMCD
complex, respectively. All experiments were conducted with
saturated solutions of estradiol. Aliquots of 1.0 mL were
withdrawn periodically and replaced with the same volume of
receptor solution. After that, samples were extracted and
analyzed by HPLC.
Pretreatment studies
In order to study the effect of HP-β-CD and RM-β-CD
on the SC barrier, the skin was kept in the diffusion cells, as
described previously, and treated with aqueous solution
containing 20% (w/v) of HP-β-CD or RM-β-CD in the donor
phase during four hours. Aqueous solution with no CD was
used as control group. Then, the skin was washed carefully
with distilled water in order to carry out permeation
experiments using saturated solution of estradiol (0.05%,
w/v) in PG:water (1:1) as donor phase.
Skin retention studies
After in vitro permeation experiments (24 h), the skin
was removed from diffusion cells and washed with water to
remove formulation excess. SC exposed to formulations
(1.77 cm2) was removed by stripping the skin 10 times with
adhesive cellophane tapes. The adhesive tapes of each skin
sample and the tape-stripped skin (epidermis plus dermis
without SC) were homogenized in methanol and maintained
in ultrasound bath for 30 min in order to extract the estradiol
retained (Surber, Schwarb, Smith, 1999). Subsequently,
samples were filtered (0.45 μm) and the amount of estradiol
was assayed by HPLC.
Data analysis
Permeation profiles of estradiol were constructed by
plotting time (hours) against the cumulative amount of the drug
(μg/cm2) measured in the receptor solution. The linear portion
of estradiol permeation profiles, with a correlation coefficient
greater than 0.90, was considered indicative of steady state
permeation and used for flux (J) determination by linear
regression, which was expressed as μg/cm2/h.
Permeation data were compared by ANOVA
followed by Tukey´s test to determine the level of
significance between CDs and control groups. The data
were considered to be significant at P<0.05.
HPLC analysis
The apparatus used for HPLC analysis was a Shimadzu
(Japan) system equipped with an LC-10AD pump and an SPD-
10A/10AV UV-Vis detector. Data acquisition was performed
with an Intralab 4290 integrator. An LiChrospher 100 C18
reverse-phase column 125 x 4 mm (5 μm) and a C18 pre-
column 4 x 4 mm (5 μm) from Merck (Darmstadt, Germany)
were used. The detection wavelength was set at 280 nm. The
mobile phase used was acetonitrile:water (60:40) in a flow rate
of 1 mL/min (Russel et al., 2000). Samples were injected
manually in a volume of 20 μL.
The estradiol contained in the receptor solution from
permeation studies was extracted using 3 mL of
chloroform. After extraction, the chloroform was
evaporated and the remaining estradiol was redissolved in
100.0 µL of mobile phase by vortexing the tubes for 1 min.
Desonide was used as internal standard (200.0 ng/mL).
The retention times for desonide and estradiol were 3.9 and
7.2 min, respectively. The method was linear at a
concentration range from 50.0 to 1000.0 ng/mL of estradiol
( y = 5.465x + 0.071, r = 0.9993). The extraction procedure
presented a recovery of 93.01%.
RESULTS AND DISCUSSION
Phase solubility studies
Figure 1 shows the aqueous phase-solubility of
estradiol at different concentrations of HP-β-CD and RM-
β-CD. Estradiol solubility increased as a function of CDs
concentration. Both complexes showed an AL type
solubility curve, which indicates that estradiol solubility
increases linearly with the increase of CD concentration,
depending on the CD aqueous solubility (Higuchi, Connors,
1965; Loftsson, Hreinsdóttir, Másson, 2005).
According to Table I, the estradiol aqueous solubility
in the presence of 50 mM of CD increased 110- and 139-
fold when HP-β-CD and RM-β-CD were used,
respectively. This difference in performance of CDs can
be related to Kc values of the complexes, which is an
empirical parameter that describes the increase in drug
apparent solubility in the presence of CDs (Higuchi,
Connors, 1965; Del Valle, 2004; Loftsson, Hreinsdóttir,
Másson, 2005). Assuming that an 1:1 complex is initially
formed, the RM-β-CD Kc value (4.23x103 M-1) was
greater than HP-β-CD (3.06x103 M-1). It has been
suggested that the spatial relationship between host and
guest molecules (steric and hydrophobic factors) was
responsible for their interaction (Higuchi, Connors, 1965;
Loftsson, Brewster, 1996; Loftsson, Hreinsdóttir, Másson,
2005). Thus, RM-β-CD solubilized estradiol better than
HP-β-CD, probably due to its larger cavity size and higher
hydrophobicity than that of HP-β-CD.
Additionally, the molar ratio of solid complexes was also
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calculated. The estradiol/HP-β-CD complex showed a mo-
lar ratio of 1:3 whereas only 2.4 moles of RM-β-CD was
necessary to solubilize one mol of estradiol. The increase in
estradiol solubility observed with both CDs may be attributed
to complex formation, but it is not enough to state that estradiol
is in the CDs cavity, since drug molecules could be interacting
with the external surface of CDs. In this way, DSC and 1H-
NMR experiments were performed in order to verify estradiol
inclusion complexation.
Differential scanning calorimetry measurements (DSC)
Thermal analyses have been described as a method
to characterize interactions between drug and CDs
molecules in solid state (Pralhad, Rajendrakumar, 2004;
Mura et al., 2005). DSC profiles of estradiol, CDs,
physical mixtures, and complexes are illustrated in Figure
2. In the estradiol thermogram, a sharp endothermic
transition at 182.6 ºC was observed, corresponding to its
melting point. The thermogram of HP-β-CD exhibited a
TABLE I - Summary of phase solubility studies
Complex Solubility enhancementa Kcb Molar ratio (E:CD)
E/HP-β-CD 110-fold 3060M-1 1:3
E/RM-β-CD 139-fold 4230M-1 1:2.4
aIn the presence of 50 mM of CD. bApparent 1:1 constant stability; E/HP-β-CD = complex of estradiol and
hydroxypropylpropyl-β-cyclodextrin; E/RM-β-CD = complex of estradiol and methylated -β-cyclodextrin.
FIGURE 1 - Solubility diagram of estradiol in the presence
of CDs. Values are expressed as mean ± S.D (n=3).
FIGURE 2 - DSC thermograms of estradiol, HP-β-CD, RM-β-CD, estradiol/CD complexes and their respective equimolar
physical mixture.
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very broad endothermic peak between 30 and 130 ºC
(maximum at 81.6 ºC), assigned to water loss (Loftsson,
Brewster, 1996). An endothermic peak at 160.6 ºC was
noticed in the RM-β-CD thermogram, which may be
associated with fusion (Moyano et al., 1997). In both
physical mixtures, two interesting events were observed:
the appearance of new endothermic transitions
(Tpeak=158.9 ºC and Tpeak=165.5 ºC for estradiol/HP-β-CD
and estradiol/RM-β-CD, respectively) and the complete
disappearance of typical estradiol and CDs endothermic
peaks. The appearance of these new transitions indicates
a possible complex formation or at least an interaction
between drug and CDs molecules in a solid state, that is,
during the physical mixture procedure.
The thermograms of both complexes also exhibited
only one endothermic peak, which was found at different
temperatures of estradiol fusion peak and CDs transitions.
In this way, based on DSC and solubility data, it could be
hypothesized that RM-β-CD interacts more favorably with
estradiol molecules forming the most stable complex, since
the estradiol/RM-β-CD complex showed a new
endothermic peak at a higher temperature (Tpeak=194.3 ºC)
than the estradiol fusion peak. In contrast, a broad peak at
lower temperature (Tpeak=140.3 ºC) was noted for
estradiol/HP-β-CD complex. Other authors have also
reported similar transitions for methylated β-CDs and HP-
β-CD inclusion complexes with apolar drugs (Green, Miller,
Guillory, 1991; Moyano et al., 1997; Vianna et al., 1998;
Pralhad, Rajendrakumar, 2004; Mura et al., 2005).
Although it was demonstrated that estradiol interacts with
CDs molecules, it is not possible to determine through DSC
analyses if estradiol enters the CDs cavity or interacts with
the external surface of CDs. To confirm that the increase
in estradiol aqueous solubility occurs due to inclusion
complexation, 1H-NMR experiments were performed.
Nuclear magnetic resonance measurements (
1
H-NMR)
1H-NMR studies provide information on the existence
of drug/CDs complexes in solution and suggest the
orientation of guest molecules into the CD cavity. 1H-NMR
results for RM-β-CD and HP-β-CD are summarized in
Table II. The 1H-chemical shifts observed for H-3 and H-
5 hydrogens of RM-β-CD and HP-β-CD, which are located
in the internal surface of CDs cavity, evidenced the estradiol
inclusion complexation with both CDs. Moreover, all RM-
β-CD hydrogens were deshielded in the presence of estradiol
TABLE II -  1H chemical shifts of free CDs and in the presence of estradiol
Hydrogen RM-β-CD E/RM-β-CD Δδ* HP-β-CD E/HP-β-CD Δδ*
complex complex
H-1 5.115 5.131 0.02 5.007 4.979 -0.03
H-2 - - - 3.706 3.677 -0.03
H-3 3.479 3.525 0.05 3.573 3.539 -0.03
H-4 - - - 3.507 3.466 -0.04
H-5 3.753 3.779 0.03 3.827 3.784 -0.04
H-6 3.849 3.885 0.04 3.975 3.938 -0.04
H-7 - - - 1.133 1.100 -0.03
H-8 - - - 5.145 5.118 -0.03
CH3O-C2,3 3.329 3.370 0.04 - - -
CH3O-C6 3.524 3.573 0.05 - - -
*Δδ (δcomplex - δ)
RM-β-CD (R= CH3)
7 8 9
HP-β-CD (R= CH2CHOHCH3)
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molecules. This behavior can be associated with a decrease
in the eletronic density around RM-β-CD hydrogens,
probably due to van der Waals forces, dipolo-dipolo
interactions and/or hydrogen bounds between drug and CDs
molecules (Másson et al., 1998; Ventura et al., 1998). On
the other hand, the presence of estradiol molecules increased
the eletronic density around HP-β-CD hydrogens, inducing
low frequency shifts as shown in Table II. Similarly, other
reports have also demonstrated low frequency shifts for
CDs hydrogens, which are considered to be induced by the
diamagnetic anisotropic effect of the aromatic moiety of
guest molecules (Dollo et al., 1996; Másson et al., 1998;
Ventura et al., 1998).
Table III shows the effects of HP-β-CD and RM-
β-CD on some estradiol hydrogens. The hydrogens present
in the aromatic moiety were shielded in the presence of
both CDs whereas H-18 present in the methyl group was
deshielded. According to Ventura et al. (1998) diamagnetic
shifts of drug hydrogens could be related to interactions
with CDs oxygen atoms, which are rich in free electrons.
Unfortunately, a conclusion could not be defined on the
way of estradiol inclusion into the CDs cavity since most
estradiol hydrogens were overlapped by those of CDs in
the NMR graphs.
The increase in estradiol aqueous solubility in addition
to changes in its thermogram due to CDs influence, and
1H-chemical shifts observed for H-3 and H-5 hydrogens
located in the internal surface of CDs cavity due to the
presence of estradiol molecules, suggest that estradiol
forms inclusion complexes with both RM-β-CD and HP-
β-CD. Moreover, the data found are corroborated by
literature (Albers, Muller, 1992).
Skin permeation/retention studies
Permeation profiles of estradiol in the free state and
complexed with RM-β-CD and HP-β-CD are displayed
by Figure 3A. The complexation with both CDs
significantly increased estradiol flux through the skin
(P<0.01). The enhancement on estradiol permeability by
CDs complexation was about 2-fold when compared with
free estradiol. Figure 3B shows the retention profile of
estradiol in the SC and tape stripped skin. The amount of
estradiol retained in the SC when complexed with HP-β-
CD was greater than when complexed with RM-β-CD or
in free state (P<0.001). No statistical difference was
observed in the amount of estradiol retained in the tape-
stripped skin (epidermis + dermis without stratum
corneum).
It has been demonstrated that some modified
β-CDs such as methylated β-CDs and hydroxypropyl-
β-CD (HP-β-CD) are capable of extracting lipids from
SC and therefore reducing the skin barrier, acting as true
absorption enhancers (Vollmer et al., 1994; Bentley et
al., 1997; Másson et al., 1999; Lopez, Collett, Bentley,
2000; Babu, Pandit, 2004). In order to verify the
influence of CDs on the SC barrier, pretreatment studies
were performed by treating the skin with aqueous
solutions containing 20% (w/v) of RM-β-CD or HP-β-
CD during 4 h before carrying out  permeation
experiments with saturated solutions of estradiol.
Vollmer et al. (1994) have demonstrated that in this
condition, the absorption of the cytochrome P450
inhibitor liarozole increased almost 10 fold in a rat
model. However, as shown in Figure 4A, RM-β-CD
pretreatment exhibited a slight enhancement in the
TABLE III -  1H chemical shifts of estradiol in the free state and in the presence of CDs
Hydrogen Estradiol E/HP-β-CD complex Δδ* E/RM-β-CD complex Δδ*
H-1 7.170 7.134 -0.04 7.132 -0.04
H-2 6.628 6.514 -0.01 6.582 -0.05
H-4 6.582 6.482 -0.02 6.521 -0.06
H-17 3.699 - - - -
H-18 0.763 0.793 0.03 0.780 0.02
*Δδ (δcomplex - δ)
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estradiol flux when compared with the control group, but
no statistical difference was found. The retention
experiments performed after  pretreatments are
illustrated in Figure 4B. RM-β-CD significantly
increased the retention of estradiol in SC (P<0.01), but
no statistical difference was observed between CDs
and control group on the amount of estradiol retained in
the tape-stripped skin.
The results obtained from retention studies indicate
that HP-β-CD and RM-β-CD are able to modify the
partitioning of estradiol into SC, but in different ways.
While complexation with HP-β-CD enhanced the amount
of estradiol retained in SC, only the RM-β-CD pre-
treatment increased hormone retention. It could be
associated with different degrees of interaction of these
CDs with skin components. Some authors have shown that
lipophilic CDs such as methylated β-CD interact better
with the skin and are able to extract lipid components from
SC (Vollmer et al., 1994; Loftsson, Másson, 2001)
whereas hydrophilic CDs interact in a lower extent with
the skin, as noted for HP-β-CD (Bentley et al., 1997;
Matsuda, Arima, 1999). Nevertheless, there are few
reports about the influence of CDs on drug retention in the
skin layers, and more studies are necessary to elucidate
their mechanism of action.
FIGURE 3 - (A) Permeation profiles of estradiol in the free
state (control group) and complexed with HP-β-CD and
RM-β-CD through hairless mouse skin. (B) Total amount
of estradiol retained in the stratum corneum (SC) and in the
tape-stripped skin (epidermis + dermis without SC) after
24h. *** indicates significant difference (P<0.01 and
P<0.001, respectively) between estradiol in the free state
and complexed with CDs. Values are expressed as means
± SEM, n=6 for each group.
FIGURE 4 - (A) Permeation profiles of estradiol after skin
pretreatment with aqueous solution (control group)
containing 20% (w/v) of HP-β-CD or RM-β-CD during 4 h
prior to the permeation experiment with estradiol saturated
solution in PG:water (1:1; v/v). (B) Total amount of
estradiol retained in the stratum corneum (SC) and in the
tape-stripped skin (epidermis + dermis without SC) after
24 h. ** Indicates significant difference (P<0.01) between
control group and RM-β-CD pretreatment. Values are
expressed as means ± SEM, n=4 for each group.
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Additionally, it has been demonstrated that
depending on the vehicle composition, CDs can either
increase or decrease drug flux through the skin. For
example, in hydrophilic ointments, HP-β-CD increased
the flux of ethyl 4-biphenylyl acetate through hairless
mouse skin, but decreased the flux from non-aqueous
PG based vehicle (Arima et al., 1998). Some reports
also showed that excess of CD, i.e. more than the
amount necessary to solubilize a lipophilic drug in an
aqueous medium, generally decreases drug penetration
through the skin (Másson et al., 1999; Loftsson,
Másson, 2001). However, Babu and Pandit (2004)
noticed a higher effect for a methylated β-CD on the
permeability of bupranolol through rat skin than HP-β-
CD, which was associated with the combined effect of
enhancing aqueous solubility of bupranolol and reducing
barrier function of the skin by methylated β-CD.
Although RM-β-CD may be able to enhance drug
flux through the skin by extracting lipid components
from SC, the results obtained in this study suggest that
the enhancing effect of HP-β-CD and RM-β-CD on
estradiol skin permeation can be mainly described as an
increase in drug availability on the skin surface due to
the inclusion complexation. Furthermore, the formation
of a significant reservoir of estradiol in the SC due to the
HP-β-CD complexation makes it  an interesting
approach to hormone replacement therapy by the
transdermal route.
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RESUMO
Efeito promotor de beta-ciclodextrinas modifica-
das na permeação in vitro do estradiol
Estradiol, o mais importante hormônio feminino, foi
complexado com hidroxipropil-β-ciclodextrina (HP-β-
CD) e metil-β-ciclodextrina randômica (RM-β-CD).
Após a obtenção dos complexos, os mesmos foram ca-
racterizados por estudos de solubilidade, CDV e RMN-
H1. O efeito das CDs sobre a absorção/retenção do
estradiol na pele foi investigado in vitro em células de
difusão de Franz. As CDs aumentaram a solubilidade
aquosa do estradiol em diferentes proporções. As aná-
lises de CVD e RMN-H1 comprovaram a complexação
do estradiol com ambas CDs, sendo que RM-β-CD
apresentou interação mais forte com estradiol do que
HP-β-CD. Mais adiante, a formação de complexos
aumentou o fluxo de estradiol através da pele (P<0,01),
mas o aumento de fármaco no estrato córneo (EC) foi
observado somente após complexação com HP-β-CD.
Por outro lado, somente a RM-β-CD foi capaz de aumen-
tar a retenção do fármaco no EC após o pré-tratamen-
to da pele com CDs. Os resultados sugerem que o efei-
to promotor das CDs no fluxo de estradiol pode ser
descrito principalmente como aumento da disponibili-
dade de fármaco na superfície da pele devido à
complexação. Além disso, a formação de um significa-
tivo reservatório do hormônio no EC torna a com-
plexação com HP-β-CD uma estratégia interessante
para liberação transdérmica do estradiol.
UNITERMOS: Estradiol. Hidroxipropil-β-ciclodextrina.
Metil-β-ciclodextrina randômica. Complexo de inclu-
são. Permeação cutânea. Promotor de absorção.
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